Saudi Hospital Seeks To Achieve Local Self-Sufficiency In Radiopharmaceuticals
KFSHRC Supplies Its Products to Nearly 50 Radiopharmaceutical Centers
At the core of this strategy is KFSHRC's Cyclotron & Radiopharmaceuticals Department, which operates three advanced cyclotrons to produce more than 35 high-quality diagnostic and therapeutic products. The department supplies around 45 medical centers and delivers daily shipments to 20 cities across the Kingdom, providing over 30,000 patient doses each year.
The hospital has also pioneered the production of critical isotopes such as iodine-123 and gallium-67, in addition to advanced therapeutic isotopes like iodine-124 and lutetium-177, which are transforming molecular imaging and targeted cancer therapies. All production follows international safety and quality standards, including GMP and ISO 9001.
KFSHRC is complementing this effort with investments in training programs in radiopharmacy, radiochemistry, and cyclotron engineering to build national expertise and long-term sustainability. Expansion plans for new cyclotron facilities in underserved regions further underline its commitment to equitable access and self-reliance in advanced healthcare solutions.
It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 20th globally in the list of the world's top 250 Academic Medical Centres for the second consecutive year and has been recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.
For more information, visit
or contact our media team at ...
Riyadh
King Faisal Specialist Hospital & Research Centre
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Kintsu Launches Shype On Hyperliquid
- Barunson, Studio Behind Parasite, To Launch Nplug IP Remixing Platform On Story And Bring Flagship IP Onchain
- Moonbirds And Azuki IP Coming To Verse8 As AI-Native Game Platform Integrates With Story
- Leverage Shares Launches First 3X Single-Stock Etps On HOOD, HIMS, UNH And Others
- Alchemy Markets Launches Tradingview Integration For Direct Chart-Based Trading
- Dexari Unveils $1M Cash Prize Trading Competition
Comments
No comment